deep dive analysi suggest corrector could
launch offer multi-billion dollar peak
sale potenti see biomark data key
catalyst could drive rais
pt remain ow
vertex develop corrector molecul treatment
antitrypsin defici aatd genet disord affect
individu aatd caus mutat gene lead
insuffici level normal protein accumul misfold
protein former caus lung damag lack render lung vulner
neutrophil elastas latter lead liver damag cirrhosi aatd
patient may exhibit either liver manifest lung manifest
current diseas modifi aatd treatment soc
chronic augment therapi deceler lung diseas progress
without address liver diseas efficaci question
case extens liver/lung damag transplant also employ variou
aatd treatment develop distinct moa includ neutrophil
elastas inhibit rna interfer gene therapi vertex current
develop differ oral administ compound aim correct
misfold therebi lead normal product discontinu
compound develop phii phi
receiv fda fast track design expect first clinic data aatd
announc
unlik investig aatd treatment vertex compound target
liver lung diseas provid prefer commerci posit
success investig aatd treatment develop
target one two aatd manifest liver lung diseas like
necessit use addit treatment aatd manifest
target experiment aatd treatment would confer
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
addit cost burden compar vertex compound target
lung-rel liver-rel manifest aatd manag
present data aatd mous model demonstr
treatment result level protect threshold
indic potenti halt lung diseas progress reduct
format toxic polym liver reflect potenti address liver
patholog although gold standard protect threshold valu
question base approv criteria exist augment
therapi believ establish aatd level suffici
demonstr efficaci fda howev believ vertex
corrector significantli differenti demonstr superior
also demonstr clinic endpoint
approv corrector could launch earli diversifi vertex
portfolio ad revenu stream overal develop corrector
molecul diseas driven protein misfold lie within vertex expertis
target aatd offer portfolio diversif vertex pipelin heavili
focus cf accord bull/base/bear case scenario current
phii launch estim risk-adjust peak
revenu believ two major catalyst could
drive revenu upsid potenti time launch especi relat
regulatori threshold approv protein level vs clinic endpoint
increas awar aatd among primari care physician current
adult aatd patient diagnos due lack aatd
awar although aatd diseas mechan distinct cf
diseas mechan believ vertex expertis develop corrector
molecul place vertex uniqu posit potenti develop success
corrector molecul aatd await first clinic data
could drive higher rais pt
account inclus risk-adjust aatd revenu
triplet approv
triplet approv uptak life-cycl manag oper margin drive
uptak life-cycl manag oper margin drive
ww penetr across cf medicin life-cycl extens extend
franchis bull case assum higher penetr tripl
therapi het/min homozygot patient initi tripl data
replic phiii therapi launch ww sale
het/min homozygot aatd addit tripl data
commerci success key
risk-adjust tripl combo success mainten key cf franchis
life-cycl extens base case assum penetr orkambi
homozyg cf patient eventu switch captur
homozyg het/min market tripl combo risk-adjust peak ww sale
tripl combin therapi aatd
modest orkambi uptak tripl combin fail achiev approv
het/min popul bear case assum row us
penetr orkambi homozyg cf patient peak ww sale
kalydeco monotherapi peak aatd therapi
peak
overweight vertex believ
initi tripl data replic phiii
studi see vertex clear leader
cf therapi believ manag
potenti deliv ep
initi phi phii data tripl
het/min popul better
kalydeco-lin efficaci
homozyg popul thu includ
risk-adjust tripl combin revenu
base case
efficaci data aatd mice model
suggest efficaci corrector human
therefor model includ risk-
adjust revenu corrector
believ potenti
competit believ vertex
signific advantag posit
on-market doubl combin in-
share competitor long-
main driver vertex phiii
tripl studi time approv launch
uptak current therapi
orkambi/kalydeco uptak in-
develop therapi tez/iva triplet
risk achiev price
combo penetr fall short
kalydeco sale fail meet
data clinic candid tripl
combin fail meet expect
data competit exce
clinic trial nda file
collabor licens agreement revenu
cost expens
product revenues/royalti
total non-gaap sg
non-gaap net incom loss continu oper
collabor revenu
st invest
cash equival
market secur avail sale
prepaid expens current asset
properti equip net
accumul comprehens incom loss
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
depreci amort expens
chang oper asset liabil
prepaid expens asset
accru expens liabil
net cash use oper activ
purchas market secur
sale matur market secur
payment acquisit variabl interest entiti
expenditur properti equip
increas decreas asset
net cash use invest activ
issuanc common stock benefit plan
payment redeem secur note
payment capit leas oblig
proce senior secur term loan
proce revolv credit facil
tax benefit stock option
net cash provid financ activ
effect exchang rate chang cash cash equival
net decreas increas cash cash equival
cash equival begin period
cash equival end period
